Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to -Mother Teresa- University Hospital in AlbaniaReportar como inadecuado




Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to -Mother Teresa- University Hospital in Albania - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background: Coronary Heart Disease CHD remains the leading cause of morbidity and mortality in Albania. According to Institute of Statistics of Albania ISA, CHD remains in the 5 first places caused mortality and morbidity in our country. Currently, all the protocol treatments to Mother Teresa University Hospital MTUH are focused on low-density lipoprotein cholesterol LDL-C as the primary target for risk reduction therapy, followed by triglycerides TG and high-density lipoprotein cholesterol HDL. Our clinicians recommend that the intensity and target goals of LDL-C-lowering therapy should be adjusted to individual treatment. The choice of a specific drug from anti hypercholesterolemia class depends on several factors which need to be evaluated better from our health providers. Methods and Findings: Data was collected between 2007 to 2015 at Mother Teresa University Hospital MTUH, Intensive Care Unit in Cardiology Clinic. 700 patients were treated with statins as follows: Fluvastain 40 mg and 80 mg, Atorvastatin 10 mg and 20 mg, Simvastatin and Rosuvastatin 20 mg. Statins are increased significantly during the years compared with fibrates. Their use grew from 87% of all statin types to 95% in 2015, with different types from fluvastatin in 2007 to atorvastatin being the leading medication in 2015. Coronary Heart Disease, especially Myocardium Infarct, were studied as diseases when meanly the hypolipidic drugs were usually used in medical protocol treatment. Statins and fibrates were the therapy target to be studied when statin dominated the patients’ treatment and fibrates were used in limited quantity. Atorvastatin is now dominating the market, while fluvastatin was on the first statin therapy for several years in the past. Fibrate were used in the modest quantities in value from 2% to 1.5% in years 2007 to 2015. The use of statins in moderate-risk and high-risk patients showed continued growth subsequently, but stable with dosage of atorvastatin 20 mg. Lower statin dosage used was independently associated for all patients, young patients had used high dosage of statins and fluvastatin respectively 40 mg and 80 mg. The missing high dosage of atorvastatin was notable. The values of LDL were improved but not in the level of efficacy of treatment. Conclusion: Statin therapy becomes more selected compared with fibrate. Atorvastatin 20 mg remains the most important stain used in our clinic, but low dosage remains still a problem. The expected level of LDL-C is the target for the practitioners. More aggressive statins such as rosuvastatin start to be present in our clinic, but it is less used by the patients. Meanwhile the lifestyle, exercises, balance diet, smoking cessation are parts of the patients’ files. The side effects are minors and the medication process has continued.

KEYWORDS

Statins, Fibrate, Coronary Heart Disease, Risk Factors, Adverse Drug Events, Etc.

Cite this paper

Shpati, K. , Prifti, R. , Shpati, D. , Bruci, Z. and Hilaj, E. 2016 Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to -Mother Teresa- University Hospital in Albania. Pharmacology & Pharmacy, 7, 236-245. doi: 10.4236-pp.2016.76030.





Autor: Kleva Shpati1, Rudina Prifti1, Dritan Shpati2, Zana Bruci3, Erina Hilaj1

Fuente: http://www.scirp.org/



DESCARGAR PDF




Documentos relacionados